Literature DB >> 27783577

Two hundred steps.

Liam Drew.   

Abstract

Mesh:

Substances:

Year:  2016        PMID: 27783577     DOI: 10.1038/538S2a

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  8 in total

1.  Staging of brain pathology related to sporadic Parkinson's disease.

Authors:  Heiko Braak; Kelly Del Tredici; Udo Rüb; Rob A I de Vos; Ernst N H Jansen Steur; Eva Braak
Journal:  Neurobiol Aging       Date:  2003 Mar-Apr       Impact factor: 4.673

2.  Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.

Authors:  Karl Kieburtz; Barbara C Tilley; Jordan J Elm; Debra Babcock; Robert Hauser; G Webster Ross; Alicia H Augustine; Erika U Augustine; Michael J Aminoff; Ivan G Bodis-Wollner; James Boyd; Franca Cambi; Kelvin Chou; Chadwick W Christine; Michelle Cines; Nabila Dahodwala; Lorelei Derwent; Richard B Dewey; Katherine Hawthorne; David J Houghton; Cornelia Kamp; Maureen Leehey; Mark F Lew; Grace S Lin Liang; Sheng T Luo; Zoltan Mari; John C Morgan; Sotirios Parashos; Adriana Pérez; Helen Petrovitch; Suja Rajan; Sue Reichwein; Jessie Tatsuno Roth; Jay S Schneider; Kathleen M Shannon; David K Simon; Tanya Simuni; Carlos Singer; Lewis Sudarsky; Caroline M Tanner; Chizoba C Umeh; Karen Williams; Anne-Marie Wills
Journal:  JAMA       Date:  2015-02-10       Impact factor: 56.272

3.  Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease.

Authors:  Jeffrey H Kordower; Yaping Chu; Robert A Hauser; Thomas B Freeman; C Warren Olanow
Journal:  Nat Med       Date:  2008-04-06       Impact factor: 53.440

4.  Alpha-synuclein in Lewy bodies.

Authors:  M G Spillantini; M L Schmidt; V M Lee; J Q Trojanowski; R Jakes; M Goedert
Journal:  Nature       Date:  1997-08-28       Impact factor: 49.962

5.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

Authors:  M H Polymeropoulos; C Lavedan; E Leroy; S E Ide; A Dehejia; A Dutra; B Pike; H Root; J Rubenstein; R Boyer; E S Stenroos; S Chandrasekharappa; A Athanassiadou; T Papapetropoulos; W G Johnson; A M Lazzarini; R C Duvoisin; G Di Iorio; L I Golbe; R L Nussbaum
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

6.  Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease.

Authors:  A L Benabid; P Pollak; A Louveau; S Henry; J de Rougemont
Journal:  Appl Neurophysiol       Date:  1987

7.  [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia].

Authors:  W BIRKMAYER; O HORNYKIEWICZ
Journal:  Wien Klin Wochenschr       Date:  1961-11-10       Impact factor: 1.704

8.  [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system].

Authors:  H EHRINGER; O HORNYKIEWICZ
Journal:  Klin Wochenschr       Date:  1960-12-15
  8 in total
  3 in total

1.  Intestinal Dopamine Receptor D2 is Required for Neuroprotection Against 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Dopaminergic Neurodegeneration.

Authors:  Hairong Peng; Shui Yu; Yukai Zhang; Yanqing Yin; Jiawei Zhou
Journal:  Neurosci Bull       Date:  2022-04-11       Impact factor: 5.271

Review 2.  Dynamic Changes in the Nigrostriatal Pathway in the MPTP Mouse Model of Parkinson's Disease.

Authors:  Dongping Huang; Jing Xu; Jinghui Wang; Jiabin Tong; Xiaochen Bai; Heng Li; Zishan Wang; Yulu Huang; Yufei Wu; Mei Yu; Fang Huang
Journal:  Parkinsons Dis       Date:  2017-07-31

Review 3.  Targeting bone morphogenetic protein signalling in midbrain dopaminergic neurons as a therapeutic approach in Parkinson's disease.

Authors:  Gerard W O'Keeffe; Shane V Hegarty; Aideen M Sullivan
Journal:  Neuronal Signal       Date:  2017-03-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.